SNX6 activators are a diverse class of chemicals that act on various biochemical and cellular pathways, primarily through the activation of key kinases and hormone receptors. These kinases and receptors play crucial roles in the internalization of receptors, a process in which SNX6 is directly involved. For instance, EGF and anandamide activate the EGFR/ERK and cannabinoid receptor/ERK pathways, respectively, leading to increased receptor endocytosis and enhanced function of SNX6.
Hormones such as estradiol, testosterone, DHT activate their respective receptors, which are involved in receptor endocytosis. Upon binding, these hormones increase receptor internalization, thereby enhancing SNX6 function. Similarly, compounds like epinephrine, forskolin, dibutyryl-cAMP, IBMX, PGE2, and rolipram regulate the cAMP pathway. The activation of this pathway leads to increased receptor endocytosis, thereby enhancing SNX6 function. As a result, SNX6 activators are capable of enhancing SNX6 function through direct or indirect interaction with the endocytic pathway. Through these cellular and biochemical pathways, SNX6 activators influence the functional activity of SNX6, emphasizing the interconnectedness of cellular signaling pathways and the possibility of enhancing a particular protein function by modulating related pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $153.00 $1224.00 $12239.00 | 82 | |
Insulin activates the PI3K/Akt pathway. SNX6, being involved in receptor trafficking, can have its function enhanced by increased endocytosis resulting from PI3K/Akt pathway activation. | ||||||
β-Estradiol | 50-28-2 | sc-204431 sc-204431A | 500 mg 5 g | $62.00 $178.00 | 8 | |
Estradiol binds to estrogen receptors that are involved in receptor endocytosis. Upon binding, there is increased receptor internalization, which can enhance the function of SNX6. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $40.00 $102.00 $197.00 $1739.00 $16325.00 | ||
Epinephrine activates the beta-adrenergic receptor, leading to increased receptor endocytosis, thereby enhancing SNX6 function. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylyl cyclase, leading to increased cAMP levels and receptor endocytosis. This can enhance SNX6 function. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
Dibutyryl-cAMP is a cell-permeable cAMP analog that can increase receptor endocytosis, thereby enhancing SNX6 function. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX inhibits phosphodiesterases, leading to increased cAMP levels and receptor endocytosis, thereby enhancing SNX6 function. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $56.00 $156.00 $270.00 $665.00 | 37 | |
PGE2 activates the EP2/EP4 receptors, leading to increased receptor endocytosis, thereby enhancing SNX6 function. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram inhibits phosphodiesterases, leading to increased cAMP levels and receptor endocytosis, thereby enhancing SNX6 function. | ||||||